Ribostamycin Free Base | CAS# 25546-65-0 (free base) | antimicrobial

MedKoo Cat#: 413500 | Name: Ribostamycin Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ribostamycin Free Base is a broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.

Chemical Structure

Ribostamycin Free Base

CAS#25546-65-0 (free base)

Theoretical Analysis

MedKoo Cat#: 413500

Name: Ribostamycin Free Base

CAS#: 25546-65-0 (free base)

Chemical Formula: C17H34N4O10

Exact Mass: 454.2275

Molecular Weight: 454.48

Elemental Analysis: C, 44.93; H, 7.54; N, 12.33; O, 35.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

25546-65-0 (free base) 53797-35-6 (sulfate)

Synonym

Ribostamycin Free Base; SF733; SF-733; SF 733

IUPAC/Chemical Name

(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((1R,2R,3S,4R,6S)-4,6-diamino-2-(((2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxycyclohexyl)oxy)tetrahydro-2H-pyran-3,4-diol

InChi Key

NSKGQURZWSPSBC-VVPCINPTSA-N

InChi Code

InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1

SMILES Code

NC[C@H]1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)N)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O[C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO)O)N)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

to be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	To be determined	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 454.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kong J, Wu ZX, Wei L, Chen ZS, Yoganathan S. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol. 2020 Jul 29;11:1718. doi: 10.3389/fmicb.2020.01718. PMID: 32849365; PMCID: PMC7403490. 2: Kurumbang NP, Liou K, Sohng JK. Biosynthesis of ribostamycin derivatives by reconstitution and heterologous expression of required gene sets. Appl Biochem Biotechnol. 2011 Feb;163(3):373-82. doi: 10.1007/s12010-010-9045-6. Epub 2010 Jul 31. PMID: 20676801. 3: Zhou SL, Shen G, Zhong HF. Pharmacokinetics of ribostamycin in paediatric patients. Clin Pharmacokinet. 1992 Feb;22(2):144-51. doi: 10.2165/00003088-199222020-00005. PMID: 1551291. 4: Horibe T, Nagai H, Sakakibara K, Hagiwara Y, Kikuchi M. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72. doi: 10.1006/bbrc.2001.6105. PMID: 11741285. 5: Fujiwara T, Tanimoto T, Matsumoto K, Kondo E. Ribostamycin production by a mutant of butirosin producing bacteria. J Antibiot (Tokyo). 1978 Oct;31(10):966-9. doi: 10.7164/antibiotics.31.966. PMID: 81827. 6: Baud H, Betencourt A, Peyre M, Penasse L. Ribostamycin, as an intermediate in the biosynthesis of neomycin. J Antibiot (Tokyo). 1977 Sep;30(9):720-3. doi: 10.7164/antibiotics.30.720. PMID: 924894. 7: Inouye S, Watanabe T, Kitasato I. Comparative antimicrobial activities of ribostamycin, gentamicin, ampicillin and lincomycin in vitro and in vivo. Drugs Exp Clin Res. 1989;15(10):465-76. PMID: 2632215. 8: Kojima M, Inouye S, Nida T. Bioconversion of ribostamycin (SF-733). III. Formation, structure and synthesis of 3-N-carboxymethyl ribostamycin. J Antibiot (Tokyo). 1975 Jan;28(1):48-55. doi: 10.7164/antibiotics.28.48. PMID: 1126867. 9: Lee SW, Han JY, Choi JS, Chung JH, Kim MY, Yang JH, Koong MK, Nava-Ocampo AA, Koren G. Pregnancy outcome of women inadvertently exposed to ribostamycin during early pregnancy: a prospective cohort study. Reprod Toxicol. 2009 Apr;27(2):196-8. doi: 10.1016/j.reprotox.2008.12.008. Epub 2008 Dec 31. PMID: 19162171. 10: Zachman-Brockmeyer TR, Thoden JB, Holden HM. The structure of RbmB from Streptomyces ribosidificus, an aminotransferase involved in the biosynthesis of ribostamycin. Protein Sci. 2017 Sep;26(9):1886-1892. doi: 10.1002/pro.3221. Epub 2017 Jul 23. PMID: 28685903; PMCID: PMC5563144.